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Background
The purpose of this study was to evaluate the use of the
pharmaceutical drug Amisulpride (Solian) in schizophre-
nic patients with resistant semiology
Materials and methods
The material of this study was 21 patients (17 men and
4w o m e n )w h ow e r ed i a g n o s e dw i t hs c h i z o p h r e n i cd i s -
order paranoid type based on DSM-IV, and were
recorded with durable symptomatology (delusions, para-
noid ideas etc.) even though the continuous issuing of
Amisulpride in normal doses (800-1200 mg/daily). In
these patients was given Amisulpride in larger doses
than the proposed (1600-2000 mg/daily). The evaluation
was done with the PANSS scale
Results
A f t e ra3 0d a yt i m ei n t e r v a la n dw h i l et h ec o n t i n u o u s
issuing of Amisulpride in larger doses was observed
considerably reprocess of the resistant symptoms, fact
that recorded at the grade alleviation at PANSS scale
Conclusions
Is concluding that the continuous issuing of Amisul-
pride in larger doses than the normal ones help consid-
erably in obliteration of the durable symptoms of
schizophrenia.
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